National policies and practices as regards the granting of and exceptions to patents, copyrights, and other types of intellectual property are often influenced by pressure from other countries. The United States is the most important source of pressure on intellectual… Continue Reading
As reported by Knowledge Ecology International (KEI), on 6 June 2017, the World Trade Organization (WTO), published a paper tabled by Brazil, China, Fiji, India, and South Africa entitled, “Intellectual Property and the Public Interest.” In their communication (IP/C/W/630), the proponents called for a series of discussions at the WTO TRIPS Council on Intellectual Property and the Public Interest. Continue Reading
The Assemblies of the Member States of the World Intellectual Property Organization (WIPO) convenes its Fifty-Fourth Series of meetings in Geneva from 22 September 2014 to 30 September 2014. These Assemblies include, inter alia, meetings of the WIPO General Assembly, the WIPO Coordination Committee, the Paris Union Assembly, the Berne Union Assembly, the Madrid Union Assembly, the Lisbon Union Assembly, the Patent Cooperation Treaty Assembly, the WIPO Copyright Treaty (WCT) Assembly and the WIPO Performances and Phonograms Treaty (WPPT) Assembly. Continue Reading
The U.S. Chamber of Commerce’s (Global Intellectual Property Center) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests USTR classify India as a Priority Foreign Country specifically citing concerns over compulsory licensing. The submission noted that India… Continue Reading
From AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 1A: 8621 Compulsory licensing of patents: 45 3D. Risk Factors The information (including tabular data) set forth or referenced under the… Continue Reading
In 2007, Thailand was involved in a dispute over the granting of compulsory licenses on medicines, including the patents used for Kaletra, an Abbott drug used in the treatment of AIDS. Kaletra is the brand name for a fixed dose combination of lopinavir and ritonavir (LPV/r) — two drugs invented at Abbott on an NIH grant. In 2007, LPV/r was the preferred combination for protease inhibitor regimes used to treat AIDS. Continue Reading
The following discusses the 2009 PhRMA submission for the USTR Special 301 list on Thailand. Thailand is one of three Asian countries (China, Philippines and Thailand) that were singled out by PhRMA for the harshest treatment. The submission on Thailand covers several topics, including these: